RecruitingPHASE1, PHASE2NCT07174583
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Studying Bronchial neuroendocrine tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IDEAYA Biosciences
- Intervention
- IDE849(drug)
- Enrollment
- 208 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, United States
- Piedmont Physicians Medical Oncology - Atlanta, Atlanta, Georgia, United States
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago, Illinois, United States
- OSF HealthCare Cancer Institute, Peoria, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne North Office, Fort Wayne, Indiana, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Trinity Health-IHA Medical Group - Hematology Oncology - Ann Arbor Campus, Ann Arbor, Michigan, United States
- The Cancer and Hematology Centers, Grand Rapids, Michigan, United States
- Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States
- Weill Cornell Medicine - Cutaneous Oncology and Melanoma Program, New York, New York, United States
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute - Oncology Partners, Nashville, Tennessee, United States
- The University of Texas MD Anderson Cancer Center Houston, Texas 77030-4000, Houston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07174583 on ClinicalTrials.govOther trials for Bronchial neuroendocrine tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07555210Pilot Study of Bone Mineral Density Changes During Anti-PD-1 ImmunotherapyJessica Mezzanotte Sharpe
- RECRUITINGPHASE1, PHASE2NCT05636618Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine TumorsPerspective Therapeutics
- RECRUITINGPHASE2NCT04665739Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT05522660Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung CancerETOP IBCSG Partners Foundation
- RECRUITINGPHASE1NCT04429087A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Boehringer Ingelheim
- ACTIVE NOT RECRUITINGPHASE1NCT02589522Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine TumorsNational Cancer Institute (NCI)
- ENROLLING BY INVITATIONNCT00068003Harvesting Cells for Experimental Cancer TreatmentsNational Cancer Institute (NCI)